Press release
Filgrastim Biosimilars Global Market Report 2024 To 2033 | Teva Pharmaceutical Industries Ltd, Novartis International AG, Biocon Limited, Intas Biopharmaceuticals
Filgrastim Biosimilars Market Share
Ready to Dive into Something Exciting? Get Your Free Exclusive Sample of Our Research Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=4016&type=smp
According to The Business Research Company's, The filgrastim biosimilars market size has grown strongly in recent years. It will grow from $1.02 billion in 2023 to $1.1 billion in 2024 at a compound annual growth rate (CAGR) of 8.0%. The growth in the historic period can be attributed to emerging markets growth, increase in patent expiration, government initiatives, increased healthcare expenditure, low cost of biosimilars, strong pipeline of drugs and increase in biopharmaceutical r&d expenditure.
The filgrastim biosimilars market size is expected to see rapid growth in the next few years. It will grow to $1.66 billion in 2028 at a compound annual growth rate (CAGR) of 10.7%. The growth in the forecast period can be attributed to aging population, increase in healthcare access,. Major trends in the forecast period include investing extensively in r&d activities for the development of effective and innovative biosimilars, production of biosimilars for neutropenia treatment to improve revenues and increasing their focus on m&a growth strategies.
Get The Complete Scope Of The Report @
https://www.thebusinessresearchcompany.com/report/filgrastim-biosimilar-global-market-report
Market Drivers and Trends:
The increasing prevalence of neutropenia is expected to propel the growth of the filgrastim biosimilar market going forward. Neutropenia refers to a condition where the body does not have enough neutrophils, which are an important type of white blood cell that fights infections. Filgrastim biosimilars work by stimulating the production of neutrophils in the bone marrow, which increases the neutrophil count and helps fight infections. For instance, in August 2022, according to the National Center for Biotechnology Information, a US-based database for biomedical literature, the prevalence of neutropenia was 0.38% among Mexican-Americans, 0.79% among whites, and 4.5% among black participants. Thus, the increasing prevalence of neutropenia is driving the growth of the filgrastim biosimilar market.
Major companies operating in the filgrastim biosimilar market are developing innovative products with advanced technologies such as recombinant DNA technology to produce biosimilars. Recombinant DNA technology is a process that involves the creation of hybrid or chimeric DNA by inserting a foreign sequence into the DNA of an organism. For instance, in May 2023, Amneal Pharmaceuticals, a US-based pharmaceutical company launched FYLNETRA (pegfilgrastim-pbbk), a biosimilar to Amgen's NEULASTA, in the United States indicated for the treatment and prevention of febrile neutropenia. It promotes the expansion and specialization of neutrophils originating from dedicated precursor cells, triggers their maturation, and improves the viability and efficiency of fully developed neutrophils, leading to dosage-dependent rises in neutrophil counts. The launch of Fylnetra contributes to the next wave of affordable medicines and drives access across patients, providers, and payors.
Key Benefits for Stakeholders:
• Comprehensive Market Insights: Stakeholders gain access to detailed market statistics, trends, and analyses that help them understand the current and future landscape of their industry.
• Informed Decision-Making: The reports provide crucial data that support strategic decisions, reducing risks and enhancing business planning.
• Competitive Advantage: With in-depth competitor analysis and market share information, stakeholders can identify opportunities to outperform their competition.
• Tailored Solutions: The Business Research Company offers customized reports that address specific needs, ensuring stakeholders receive relevant and actionable insights.
• Global Perspective: The reports cover various regions and markets, providing a broad view that helps stakeholders expand and operate successfully on a global scale.
Major Key Players of the Market:
Inditex (Zara), H&M Group, The Gap, Inc., Fast Retailing (Uniqlo), Associated British Foods plc (Primark), ASOS Plc, Urban Outfitters, Mango, New Look, Esprit, C&A, Forever 21, Esprit Holdings Limited, Gap Inc., Cotton On Group, Topshop, Bershka, Levi Strauss & Co, United Arrows Ltd., Allen Solly, Future Lifestyle Fashions, Jack Wills, Boohoo Group, Debenhams, Topshop, MoroZoni, Colin's, Diesel, Wrangler, Rifle, Gloria Jeans, LPP SA., Aeropostale, American Eagle Outfitters, Abercrombie & Fitch, Ralph Lauren, Old Navy, Nike, Calvin Klein, Zumiez, Converse, Hollister, Houpa, Adidas, Puma, WinCraft, Gildan Activewear, Chanel, Reinaldo Lourenço, Colcci, Havaianas, Zadea Group, Osman Jamjoom Group, Next
Filgrastim Biosimilars Market 2024 Key Insights:
• The filgrastim biosimilars market size is expected to see rapid growth in the next few years. It will grow to $1.66 billion in 2028 at a compound annual growth rate (CAGR) of 10.7%.
• Neutropenia Prevalence Drives Growth In The Filgrastim Biosimilar Market
• Amneal Pharmaceuticals' Fylnetra Marks A New Era Of Accessible Healthcare With Recombinant Dna Technology
• North America was the largest region in the filgrastim biosimilar markets market in 2023
We Offer Customized Report, Click @
https://www.thebusinessresearchcompany.com/Customise?id=4016&type=smp
Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Filgrastim Biosimilars Global Market Report 2024 To 2033 | Teva Pharmaceutical Industries Ltd, Novartis International AG, Biocon Limited, Intas Biopharmaceuticals here
News-ID: 3765883 • Views: …
More Releases from The Business research company
Key Factor Supporting Global ERP Software Market Development in 2025: Expanding …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the ERP Software Industry Market Size Be by 2025?
The size of the erp software market has expanded swiftly in the preceding years. It is projected to surge from $145.29 billion in 2024 to $159.87 billion in 2025, reflecting a compound annual growth rate (CAGR) of 10.0%.…
The Rising Need For Low Operating Costs In Business Process As A Service (Bpaas) …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Business Process as a service (BPaaS) Market Through 2025?
Over time, there has been consistent growth in the business process as a service (BPaaS) market size. The market, currently valued at $57.49 billion in 2024, is anticipated to grow to $59.98 billion…
2025-2034 Augmented Reality Services Market Outlook: Key Drivers, Emerging Chall …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Augmented Reality Services Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size of augmented reality services has seen substantial growth in the past few years. The market size, which was at $194.44 billion in 2024, is projected to reach $280.66 billion in 2025,…
Rising Demand For Industrial Internet Of Things (IIoT) Driving Growth Of The Tim …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Time-Sensitive Networking (TSN) Market Size Growth Forecast: What to Expect by 2025?
The exponential expansion of the time-sensitive networking (tsn) market in recent years is noteworthy. The market, which was valued at $0.65 billion in 2024, is estimated to swell up to $0.81 billion in 2025, reflecting a compound…
More Releases for Filgrastim
Filgrastim Injection Market Is Booming So Rapidly with Amgen, Sandoz, Teva Pharm …
HTF Market Insights just released the Global Filgrastim Injection Market Study, a comprehensive analysis of the market that spans more than 143+ pages and describes the product and industry scope as well as the market prognosis and status for 2025-2032. The marketization process is being accelerated by the market study's segmentation by important regions. The market is currently expanding its reach.
Major companies Filgrastim Injection Market are:
Amgen, Sandoz, Teva Pharmaceutical,…
2024 Filgrastim Biosimilars Market: Size, Growth, Share, Trends, Forecast To 203 …
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Filgrastim Biosimilars Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $1.66 billion In 2028 At…
Filgrastim Biosimilars Global Market Analysis, Trends, Growth, Research And Fore …
The filgrastim biosimilars market size has grown strongly in recent years. It will grow from $1.02 billion in 2023 to $1.1 billion in 2024 at a compound annual growth rate (CAGR) of 8.0%. The growth in the historic period can be attributed to emerging markets growth, increase in patent expiration, government initiatives, increased healthcare expenditure, low cost of biosimilars, strong pipeline of drugs and increase in biopharmaceutical r&d…
Filgrastim Biosimilars Market Size, Share And Trends Analysis Report 2024-2033
The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2033
The Business Research Company presents an extensive market research report on the Filgrastim Biosimilars Global Market Report 2024, furnishing businesses with a competitive edge through a detailed examination of the market structure, encompassing estimates for various segments and sub-segments.
Furthermore, the report highlights on emerging trends, significant drivers, challenges, and opportunities,…
Filgrastim Market Is Likely to Experience a Tremendous Growth by 2029
Filgrastim Market was valued at USD 992.8 million in 2022 and is expected to grow at a CAGR of 8% between 2023 and 2029. Filgrastim Market research involves carrying out thorough research on market to help newly emerging players in making calculated decision regarding which business ideas to follow. It is carried out to assess the viability of novel product or service. There are a few important goals can be…
Filgrastim Market Report, History and Forecast 2023-2031
The report extensively examines the global Filgrastim market while focusing on the leading companies and their business strategies, geographical growth, market segmentation, competitive environment, production, price, and cost structures. Each section of the research report has been carefully designed to examine important facets of the global market for Filgrastim. For instance, the market dynamics section delves deeply into the trends, opportunities, and drivers influencing the global market for Filgrastim. We…
